Direkt zum Inhalt
Merck
Alle Fotos(4)

Wichtige Dokumente

Gesamtdokumentation anzeigen

R116

Sigma-Aldrich

Riluzol

≥98% (HPLC), solid, glutamate release inhibitor

Synonym(e):

2-Amino-6-(trifluormethoxy)-benzothiazol

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(4)

About This Item

Empirische Formel (Hill-System):
C8H5F3N2OS
CAS-Nummer:
1744-22-5
Molekulargewicht:
234.20
MDL-Nummer:
MFCD00210213
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24278006
NACRES:
NA.77

Produktbezeichnung

Riluzol, solid

Form

solid

Qualitätsniveau

100

Ersteller

Sanofi Aventis

SMILES String

Nc1nc2ccc(OC(F)(F)F)cc2s1

InChI

1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

InChIKey

FTALBRSUTCGOEG-UHFFFAOYSA-N

Angaben zum Gen

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
rat ... Scnn1g(24768)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Glutamate release inhibitor; anticonvulsant

Leistungsmerkmale und Vorteile

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Skull and crossbones
GHS06

Signalwort

Danger

H-Sätze

H300

Gefahreneinstufungen

Acute Tox. 2 Oral

Lagerklassenschlüssel

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Persönliche Schutzausrüstung

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
SLCL3154
SLCK9186
057K3900V
104K3851
096K3900

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 3

1 of 3

Risperidon ≥98% (HPLC), powder

Sigma-Aldrich

R3030

Risperidon

(±)-Baclofen ≥98% (HPLC), solid

Sigma-Aldrich

B5399

(±)-Baclofen

Dulbecco Modifiziertes Eagle-Medium – hoher Glucosegehalt With 4500 mg/L glucose, L-glutamine, and sodium bicarbonate, without sodium pyruvate, liquid, sterile-filtered, suitable for cell culture

Sigma-Aldrich

D5796

Dulbecco Modifiziertes Eagle-Medium – hoher Glucosegehalt

Maurizio Anzini et al.
Journal of medicinal chemistry, 53(2), 734-744 (2009-12-03)
A series of amidine, thiourea, and guanidine derivatives of 2-amino-6-(trifluoromethoxy)benzothiazole termed 2, 3, and 4, respectively, and structurally related to riluzole, a neuroprotective drug in many animal models of brain disease, have been synthesized. The biological activity of compounds 2a-e
Ryan S Phillips et al.
eLife, 11 (2022-07-08)
Previously our computational modeling studies (Phillips et al., 2019) proposed that neuronal persistent sodium current (INaP) and calcium-activated non-selective cation current (ICAN) are key biophysical factors that, respectively, generate inspiratory rhythm and burst pattern in the mammalian preBötzinger complex (preBötC)
Michael G Fehlings et al.
Journal of neurosurgery. Spine, 17(1 Suppl), 151-156 (2012-09-19)
In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective
Gwen Schwartz et al.
Progress in brain research, 137, 177-190 (2002-11-21)
Traumatic spinal cord injury is a consequence of a primary mechanical insult and a sequence of progressive secondary pathophysiological events that confound efforts to mitigate neurological deficits. Pharmacotherapy aimed at reducing the secondary injury is limited by a narrow therapeutic
Mark C Bellingham
CNS neuroscience & therapeutics, 17(1), 4-31 (2010-03-20)
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disease of adults which preferentially attacks the neuromotor system. Riluzole has been used as the only approved treatment for amyotrophic lateral sclerosis since 1995, but its mechanism(s) of action in
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.